PureTech´s Microbiome Programme Advances into a Phase 1a/1b Clinical Trial
(World News Science)

VE303 is first known rationally-defined bacterial consortium in powder form to enter the clinic and has received Orphan Drug Designation from the US FDA for C. difficile indication PureTech Health plc (LSE: PRTC), an advanced, clinical-stage biopharmaceutical company, is pleased to note that Vedanta Biosciences, an affiliate of PureTech Health, today announced the initiation of a Phase 1a/1b clinical trial of VE303, the Company`s lead, orally-administered, human microbiome-derived product candidate. VE303 is the first known investigational drug consisting of rationally-defined bacterial consortium in powder form to enter the clinic. It is comprised of a group of bacteria selected based on...